|
|
|
|
|
CUSIP No. 483497 10 3 |
|
13D |
Item 1. Security and Issuer
This joint statement on Schedule 13D/A (this Statement) is filed with respect to the common stock, par value $0.001 per share (Common
Stock), of KalVista Pharmaceuticals, Inc., a Delaware corporation (the Issuer). The address of the principal executive offices of the Issuer is 55 Cambridge Parkway, Suite 901 East, Cambridge, MA 02142. Information given in
response to each item shall be deemed incorporated by reference in all other items, as applicable.
Except as set forth above, the Reporting Persons have
no present plans or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.
Item 2. Identity and Background.
(a) This
Amendment No. 1 (Amendment No. 1) amends and supplements the Schedule 13D originally filed with the Commission on January 9, 2023 (the Original Schedule 13D). This Statement is being filed by TCG Crossover Fund
I, L.P. (TCG Crossover I), TCG Crossover GP I, LLC (TCG Crossover GP I and together with TCG Crossover I, the Reporting Entities) and Chen Yu (the Reporting Individual). The Reporting Entities and the
Reporting Individual are collectively referred to as the Reporting Persons. The agreement among the Reporting Persons to file jointly in accordance with the provisions of
Rule 13d-1(k)(1) under the Act is attached to Original Schedule 13D as Exhibit 1. Each Reporting Person disclaims beneficial ownership of all securities reported in this Statement except
to the extent of such Reporting Persons pecuniary interest therein, other than those securities reported herein as being held directly by such Reporting Person.
Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13D remain unchanged. Information given in response
to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment have the meanings ascribed to them in the Original Schedule 13D. This Statement is being filed to reflect the
sales of shares of Common Stock of the Issuer by the Reporting Persons that occurred between January 25, 2024 and February 16, 2024, as well as to reflect an increase in the number of shares of Common Stock outstanding, caused by, among
other things, the Issuers sales of additional shares of its Common Stock from time to time since the date of the filing of the Original Schedule 13D.
Item 5. Interest in Securities of the Issuer
Item
3(c) of the Original Schedule 13D is hereby amended to add the following language:
(c) Except as otherwise reported in this Statement, none of the
Reporting Persons has effected any transactions in the Issuers securities within the past 60 days.
TCG Crossover I made the following open market
sales of Common Stock between January 25, 2024 and February 16, 2024.